A New Probiotic Formulation Promotes Resolution of Inflammation in a Crohn's Disease Mouse Model by Inducing...

Area of Science:

• Gastroenterology
• Immunology
• Microbiome Research

Background:

• Gut microbiome dysregulation is central to Crohn's disease (CD) pathogenesis.
• Altered immune responses and unresolved inflammation characterize CD.
• Targeting the gut microbiome offers a potential therapeutic strategy for CD.

Purpose of the Study:

• To evaluate the immunomodulatory effects of a novel probiotic + amylase blend.
• To assess the efficacy of this blend in a mouse model of CD-like ileitis.
• To investigate the impact of the blend on immune cell populations and inflammatory pathways.

Main Methods:

• Utilized the SAMP1/YitFc mouse model for CD-like ileitis.
• Administered probiotic + amylase blend, probiotics alone, amylase alone, or PBS for 56 days.
• Performed histological evaluation and GeoMx Digital Spatial Profiler (DSP) analysis on ileal tissues.

Main Results:

• The probiotic + amylase blend significantly reduced ileitis severity compared to controls.
• DSP analysis revealed decreased neutrophils and increased dendritic cells, regulatory T cells, and macrophages.
• Enrichment of apoptosis-related pathways was observed, confirmed by TUNEL assay.

Conclusions:

• The probiotic + amylase blend demonstrates a beneficial role in resolving ileitis.
• The blend enhances apoptosis in innate immunity-associated cells, modulating the immune response.
• This formulation is a promising candidate for clinical trials in managing Crohn's disease.